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Abstract
Background: Interpretative commenting is an impor-
tant activity of the clinical diagnostic laboratory. We
describe a study of interpretative commenting abili-
ties among senior laboratory professionals in the
Asia-Pacific region and Africa.
Methods: Five sets of laboratory results reflecting
common and important problems encountered in
clinical chemistry were distributed at 4-weekly inter-
vals to 31 registered participants from countries in the
Asia-Pacific region and Africa. Participants were
asked to attach an interpretative comment to the
results assuming that the requesting doctor had
asked for an interpretation of the result.
Results: Twelve pathologists and 19 scientists from
seven countries registered to participate and the over-
all reply rate was ;50% for the five cases. The quality
of the comments returned by participants was diverse
and some reflected incorrect or misleading interpre-
tation and advice.
Conclusions: While interpretative commenting is an
important laboratory activity, the results of this study
suggest that there is room for improvement in the
quality of interpretative comments offered by senior
laboratory professionals, even for commonly report-
ed results relating to most prevalent and important
public health conditions. Interpretative commenting
should be formally taught during training of patho-
*Corresponding author: Dr. Samuel D. Vasikaran,
Department of Core Clinical Pathology and Biochemistry,
Royal Perth Hospital, Box X2213 GPO, Perth, WA 6847,
Australia
Phone: q61 8 9224 2453, Fax: q61 8 9224 1789,
E-mail: samuel.vasikaran@health.wa.gov.au
Received April 15, 2009; accepted May 25, 2009;
previously published online July 10, 2009
logists and scientists, and continuing professional
development in this area is required for the provision
of a quality interpretative service.
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Introduction
The role of the clinical diagnostic laboratory includes
offering advice on the selection and interpretation of
laboratory tests. While most anatomical pathology
laboratory reports carry an interpretative comment,
clinical pathology reports mostly do not, nor is this
possible given the volume of reports produced. How-
ever, clinicians appreciate receiving interpretative
comments on the more complex tests and feel that
they help or influence patient management, save
them time, and improve the diagnostic process (1, 2).
While there are no randomized control studies to con-
firm the effectiveness of interpretative comments on
improving outcomes, there are some observational
data to suggest that this may be the case (3). This is
not surprising given that doctors at graduation often
lack adequate training in test ordering and result
interpretation (4). However, inappropriate comment-
ing by inadequately trained laboratory personnel can
be dangerous (5, 6). Training in pathology consulta-
tion has to be undertaken in a formal manner for this
activity to be performed effectively (7). There is now
some acceptance in the clinical chemistry profession
for the need and ability to assess the quality of inter-
pretative services offered by the clinical chemistry
laboratory (6, 8, 9). We describe a study of interpre-
tative commenting ability among laboratory person-
nel in the Asia-Pacific region and Africa.
Materials and methods
Expressions of interest were invited from individuals and
laboratories from the Asia-Pacific region via the Asian and
Pacific Federation of Clinical Biochemistry (APFCB) council
representatives and the APFCB Committee on Laboratory
Management (C-LM) representatives of each country to
participate in the Commenting Educational Program. The
representative from each APFCB member country had dis-
cretion to decide on how to publicize this program and invite
participants in their country. Participation was free, but prior
registration with the APFCB C-LM was required.
One set of laboratory results with some clinical back-
ground was distributed by e-mail to registered participants
5 times during 2008 at approximately 4-weekly intervals. The
964 Vasikaran et al.: Interpretative commenting in the Asia-Pacific region
Article in press - uncorrected proof
Table 1 A sample of a case report distributed to partici-
pants.
Asian and Pacific Federation of Clinical Biochemistry
APFCB Laboratory Management Committee (C-LM) Project
Interpretative Comments Educational Program
July 2008
Case 3
Patient: 47-year-old man, requested by family practitioner
Clinical history: Health check
Results:
Serum Reference range
PSA 3.2 mg/L -4.0 mg/L
Additional information: No previous PSA result available
for this patient. Other results, glucose and lipids, were
unremarkable.
Please assume that the attending doctor has requested
an interpretation of the PSA test result. State your inter-
pretative comment for the PSA test result (maximum 500
characters including spaces)
PSA, prostate specific antigen.
Table 2 The cases that were distributed in the program.
Case 1
Patient: 56-year-old woman, referred by general
practitioner for oral glucose tolerance test
Clinical history: Family history of diabetes mellitus
Results: 75 g oral glucose tolerance test.
Venous plasma: 0 min glucose 6.6 mmol/L
60 min glucose 13.4 mmol/L
120 min glucose 7.1 mmol/L
Previous results: Random blood 7.4 mmol/L
glucose
Case 2
Patient: 37-year-old woman, requested by family
practitioner
Clinical history: Attempting to conceive? Small goiter
Results:
Serum Reference range
FT4 13 pmol/L 9–21 pmol/L
TSH 5.2 mU/L 0.4–4.0 mU/L
Additional information: Other results, FBE, U&E and
glucose were all normal.
Case 3
Patient: 47-year-old man, requested by family practitioner
Clinical history: Health check
Results:
Serum Reference range
PSA 3.2 mg/L -4.0 mg/L
Additional information: No previous PSA result available
for this patient. Other results, glucose and lipids, were
unremarkable.
Case 4
Patient: 76-year-old man, requested by family practitioner
Clinical history: Health check
Results:
Serum Reference interval
Sodium 139 mmol/L (134–146) mmol/L
Potassium 3.8 mmol/L (3.4–5.0) mmol/L
Glucose 4.6 mmol/L (3.0–5.4) mmol/L
Bicarbonate 27 mmol/L (22–32) mmol/L
Urea 6.8 mmol/L (3.0–8.0) mmol/L
Serum creatinine 131 mmol/L (60–110) mmol/L
eGFR 49 mL/min/1.73 m2
Additional information: Previous serum creatinine 128
mmol/L 12 months ago. Urine microscopy unremarkable.
Spot urine protein 7 mg/mmol creatinine (-13).
Case 5
Patient: 56-year-old male, requested by family practitioner
Clinical history: CHD on lipid lowering therapy
Results:
Fasting plasma Reference interval
Total cholesterol 4.6 mmol/L -5.2 mmol/L
Triglyceride 1.4 mmol/L -2.0 mmol/L
LDL-C (calc) 2.9 mmol/L -3.4 mmol/L
HDL-C 1.2 mmol/L )1.0 mmol/L
PSA, prostate specific antigen; FT4, free thyroxin; TSH, thy-
roid stimulating hormone; eGFR, estimated glomerular filtra-
tion rate; CHD, coronary heart disease; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol; FBE, full blood examination; U&E, urea and
electrolytes.
format of the report was an electronic version of a set of
laboratory results together with any relevant clinical infor-
mation (Table 1). Participants were invited to assume that
the requesting doctor had asked for an interpretation of the
results and were asked to attach an interpretative comment
(maximum 500 characters including spaces) to the report
and return to the organizers by e-mail within a fortnight. This
may represent a written, printed or verbal comment from the
reporting laboratory (Pathologist/Scientist) to the requesting
doctor. A total of five cases were circulated over 5 months
(Table 2).
Once the replies from participants were received, they
were reviewed by the Commenting Educational Program
Committee (consisting of SDV, KAS, LCL and SS). An exam-
ple of a good interpretative comment and an overview and
discussion of the case, together with reference to any rele-
vant publications, were returned to participants by e-mail
within a few weeks of the closing date for replies. Anonymity
of participants was maintained. Thus, participants were able
to review their interpretation of results and communication
to the requesting doctor and compare it with current best
practice in the opinion of the Program Committee. For the
purpose of this publication, the individual comments were
scored on a scale of 0–4 (0 being a bad comment and 4 an
ideal comment) independently by two members of the Pro-
gram Committee and the scores averaged. The scoring of
comments by the two committee members were compared
by statistical analysis. The average score for all the com-
ments by participants who were pathologists was calculated
and compared with the average score for all comments by
participants who were scientists (Student’s t-test).
Results
A total of 31 people registered for the program; 27
were from the APFCB region and an additional four
people from Africa who had heard about the program
by word of mouth also registered after the program
had started (Table 3). Most of the participants were
senior laboratory staff, with 12 of the registrants
being pathologists and 19 scientists. A sample of
replies received from participants together with the
mean score awarded to each comment by the com-
mittee are listed in Tables 4–8 (comments longer than
500 characters have been truncated at 500) together
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Table 3 The number of participants listed by country of
origin.








Table 4 Examples of participant comments with designation of participant (DsMedical, SsScientist) and mean score given




S 0 This is a case of ‘‘impaired glucose tolerance (IGT) and mild diabetes.’’ At this stage the patient does not
S 1 Patient’s fasting glucose is high but 2 h post 75 g glucose result is lower than the diabetic diagnosis
criteria (-7.7). This condition shows that patient is having impaired glucose tolerance. Suggest to do
serum insulin.
D 2 Laboratory diagnosis impaired glucose tolerance. The accepted fasting, 1st and 2nd hour levels are 5.5,
9.4 and 7.7 mmol/L, respectively. The fasting is higher than the normal reference range. The 2nd hour
sample is well within the acceptable range of 7.7.
S 3 The report revealed that patient had impaired fasting glucose (IFG) levels and 60 min levels suggest lag
storage response. It is recommended to undergo repeat oral glucose tolerance testing (OGTT) after
6 months for follow-up.
D 4 This patient has an IFG on her OGTT. It is recommended that the OGTT be repeated annually and she be
advised on lifestyle modification and cardiovascular risk factors assessment.
Comment drafted by the Program Committee
This patient has an IFG on her OGTT. It is recommended that the OGTT be repeated annually and she be advised on
lifestyle modification and cardiovascular risk factors assessment.
with the comment composed by the Program Com-
mittee for each case. Participation fluctuated at
around 50% which, while disappointing, is not dissim-
ilar to other programs where participants pay to
register (6).
Case 1
The first case had 14 responses out of which 10 had
a diagnosis of impaired fasting glycemia (IFG) (Table
4). One comment had a diagnosis of ‘‘borderline dia-
betes’’, one ‘‘mild diabetes’’, one ‘‘slightly high fast-
ing glucose’’ and two had impaired glucose tolerance
(IGT). Suggestions for further investigations included
measurement of insulin in one comment, ‘‘urine
sugar’’ in one, repeat fasting glucose without a time
stipulation, or at 1 or 6 months, and repeat oral glu-
cose tolerance testing (OGTT) at 1 or 12 months. Five
of the comments had no suggestion for further inves-
tigation or follow-up. Only five comments had sug-
gestions for lifestyle modification.
Case 2
The second case elicited 16 responses which included
a diagnosis of subclinical hypothyroidism in 10 com-
ments, hypothyroidism in one comment, ‘‘normal
results’’ in one comment and early or mild hypothy-
roidism in three comments (Table 5). Four comments
included a suggestion to consider replacement ther-
apy, seven suggested repeat testing, six suggested
thyroid peroxidase (TPO) antibody testing and two
each suggested free triiodothyronine (FT3) testing or
imaging studies. One comment had a diagnosis only
with no suggestion for further investigation or follow-
up.
Case 3
This case elicited 17 responses, 12 of which stated
that the result would be above the age related upper
reference limit (Table 6). Two comments stated the
results were normal and two suggested the results
indicated benign hyperplasia. Three comments listed
other causes for a transient increase in prostate spe-
cific antigen (PSA). Eight comments suggested per-
forming a free PSA (fPSA) measurement and 11
suggested repeat PSA testing ranging from 1 week,
1 month, and 6 months to 1 year. One comment
included an overt suggestion for urology referral
while three suggested prostatic biopsy, four advised
digital rectal examination (DRE) and two an ultra-
sound examination.
Case 4
We received 15 responses of which seven referred to
decreased renal function or estimated glomerular fil-
tration rate (eGFR) and five mentioned stage 3 chronic
kidney disease (CKD) while one referred to grade 2
CKD and five stated the renal function was normal for
the patient’s age (Table 7). Only one comment men-
tioned race may be a confounder, as the estimate may
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Table 5 Examples of participant comments with designation of participant (DsMedical, SsScientist) and mean score given




S 0.5 This euthyroid might be a normal condition for a lady trying to conceive. The cause of goiter must be
investigated to prevent it from becoming larger. She might be having iodine deficiency but repeat testing
are recommended together with free T3 (FT3) to rule out thyrotoxicosis or early sign of hypothyroidism.
D 1 Patient has a subclinical hypothyroid state. Needs to repeat thyroid stimulating hormone (TSH) and free
T4 (FT4) within 2–12 weeks. Suggest a lipid profile as well.
S 2 This can be a case of sub-clinical hypothyroidism. The usual procedure is to repeat the TFT so as to rule
out transient thyroiditis or laboratory error when the TSH becomes normal. For this case, since the patient
is attempting to conceive and with a small goiter, thyroxine therapy is recommended. But some argue
against this treatment since there is very limited evidence of the benefit of treatment. An additional test
that can be done is thyroid microsomal antibody. A positive result will support wTruncatedx.
D 3 The mildly elevated TSH with normal FT4 is suggestive of subclinical hypothyroidism. Thyroid peroxidase
(TPO) antibody and lipid profile may be useful in this patient. Thyroid hormone replacement should be
considered in this patient if TSH remains persistently elevated as she is attempting to conceive in view of
potential effects on fetal health of untreated maternal hypothyroidism.
Comment drafted by the Program Committee
Borderline increase in TSH can occur following recovery from illness, or with early thyroid failure. Consider iodine
deficiency, and TPO antibody testing. Consider T4 replacement to achieve TSH -2.6 mU/L in view of potential effects on
fetal health of maternal hypothyroidism.
TFT, thyroid function test; FT3, free triiodothyronine; FT4, free thyroxine.
Table 6 Examples of participant comments with designation of participant (DsMedical, SsScientist) and mean score given




S 0 The PSA value is in normal range. It shows that patient is not having any malignancy prostate problem,
but in this age group he should get it repeated every year for further safety, as this age group can have
risk.
S 1 It is a borderline PSA result. The test may be repeated to see whether there is serial rise in PSA.
D 2 Although the total PSA value is below the reference range for the general population, it is high for the
patient’s age. This may, however, be due to benign prostatic hyperplasia. I recommend that prostate ultra-
sound should be done. A repeat PSA should also be done after 6 months to assess the PSA velocity.
D 2.5 PSA level exceeds the upper limit of normal for age range. Free PSA may help to differentiate between
benign prostatic enlargement and cancer.
S 3.5 PSA value of 3.2 mg/L cannot rule out prostatic cancer in this age group. Family history of prostate
cancer, an abnormal DRE and results of previous prostate biopsy if any help assessment of caner risk.
PSA density and free-to-total PSA fraction ratio assays may further delineate risk level. Based on risk level
and patient’s understanding of the consequences of a cancer diagnosis, he can best determine whether
urology referral for a prostate biopsy or expectant management wTruncatedx.
Comment drafted by the Program Committee
PSA increased above age related upper reference limit of 2.5 mg/L for 40–49-year-old men. PSA can be raised up to 6–48 h
after ejaculation. Other causes of a significant rise in PSA are urinary infection, prostatitis, prostatic massage (not DRE) and
bicycle riding. Consider DRE and referral to urologist. Free PSA may help risk stratification.
PSA, prostate specific antigen; DRE, digital rectal examination.
not be appropriate for blacks. None of the comments
mentioned the appropriateness or otherwise of the
estimate in an Asian population. Six comments men-
tioned that creatinine was stable in the last 12 months
and eight comments mentioned diabetes and/or
hypertension as possible causes of renal damage.
Three comments suggested there was likely to be no
renal damage, and all the comments had suggestions
for further evaluation, investigation or follow-up.
Three comments suggested avoiding nephrotoxic
drugs, two suggested ultrasound investigation and
two advised specialist referral. One comment advised
GFR measurement.
Case 5
The fifth and final case elicited 13 responses of which
nine stated the low-density lipoprotein (LDL) was
above target value (Table 8). Four suggested reviewing/
optimizing drug therapy, three suggested reviewing
lifestyle measures and two suggested looking at sec-
ondary causes. Two advised checking liver function
tests and/or muscle enzymes. Four comments stated
that target value had been achieved and one of these
suggested a trial cessation of lipid lowering therapy.
Two comments advised measures to increase high-
density lipoprotein (HDL).
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Table 7 Examples of participant comments with designation of participant (DsMedical, SsScientist) and mean score given




D 0.5 Mild elevation of urea and rising serum creatinine indicate underlying renal involvement. Mild elevation of
serum creatinine does not correlate with significant reduction in renal function reflected by eGFR. This is
because eGFR estimations are not reliable at extreme of age. Suggest 24-h urine collection for creatinine
clearance or serum cystatin C level, serum PSA assay and ultrasound scan of the abdomen.
S 1 This case represents stage 3 chronic kidney disease (CKD). Stage 3 CKD is moderately reduced kidney
function. Since the patient represents: (1) moderately reduced kidney function, (2) moderate elevation of
serum creatinine for )1 year and eGFR value he can be classified under stage 3 CKD.
S 2 Patient suffers stage 3 CKD with moderate decrease in kidney function. CKD risk factors including diabetes
mellitus, hypertension, smoking history and family history of kidney disease should be screened for.
Renal function test, urine protein and urinalysis should be performed with blood pressure and blood glu-
cose monitored serially. Advise patient to avoid nephrotoxic drugs and ensure drug dosages appropriate
for level of renal function. Early referral to nephrologist wTruncatedx.
D 2.5 Although the urea and creatinine levels are slightly raised above the reference range, the eGFR value can
be considered as for the age group if it is documented to be stable over time and unaccompanied by
other evidence of renal damage. Any reversible element of renal impairment e.g., hypertension, urinary
tract infection and benign prostatic hypertrophy should be considered. It is advisable to monitor the renal
function of the subject every 3 months.
Comment drafted by the Program Committee
The MDRD equation for estimating GFR has been validated in Caucasians only. An eGFR of 49 mL/min/1.73 m2 in a 76-year-
old man when stable over time with no other evidence of kidney damage, and in the absence of hypertension and diabetes
and structural abnormalities, may be normal for his age and unlikely to be associated with CKD complications. Suggest
renal ultrasound and repeat eGFR in 6 months.
eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
Table 8 Examples of participant comments with designation of participant (DsMedical, SsScientist) and mean score given




S 0.5 Results show patient is on optimum dose, effort can be done to lower or stop therapy with close
monitoring of follow-up lipid profile and patient’s diet control.
S 1 The HDL values are low which is protective. Rest values on lipid lowering therapy are maintained. Patient
has to be advised for increasing (HDL)-cholesterol.
D 2 According to the guidelines recommended by the National Heart Foundation of Australia, reduction of his
LDL cholesterol -2 mmol/L is beneficial as he is a known patient with coronary heart disease (CHD).
S 3 The male patient is at highest risk for CHD and his LDL-cholesterol level should be less than target goal of
2.59 mmol/L. It is recommended to increase the dose of cholesterol lowering therapy and monitor after
3 months.
S 4 According to National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III guideline,
target level of LDL-C for patients with CHD is -2.6 mmol/L with an optional target at 1.8 mmol/L. Advice on
lifestyle modification and adjustment of dosage of lipid lowering drug are recommended. Please monitor
liver enzyme and creatine kinase activities while on lipid lowering agents.
Comment drafted by the Program Committee
The recommended optimal targets for LDL cholesterol in a patient with CHD is -2.6 mmol/L. Suggest review of lipid
lowering therapy and therapeutic lifestyle changes for compliance and optimization.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
The two members of the Program Committee who
independently scored comments gave identical
scores for 35 out of the total of 75 comments and
gave scores that were different by one for the rest of
the comments, with each adjudicator giving a higher
score for an equal number (ns20) of comments. The
Wilcoxon sign rank test showed no difference in the
scores: z-value 0.2688 (0.7872-p-0.7949) and Spear-
man’s rank order correlation was 0.6633 (p-0.001).
The mean scores obtained by medically trained par-
ticipants (2.0) was not significantly different from the
mean score obtained by scientifically trained partici-
pants (1.8).
Discussion
Interpretative commenting is an integral part of the
activities and responsibilities of the clinical diagnostic
laboratory. Our program was developed as an edu-
cational activity for interested participants from the
Asia-Pacific region, but the results also provide a
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Table 9 A brief discussion of the five cases circulated in the program.
Case Discussion of case
number
1 The WHO defined values for IFG are a fasting plasma glucose nconcentration in the range of 6.1–6.9 mmol/L,
and a 2-h post-glucose load (if measured) -7.8 mmol/L (11). The alternative definition of IFG by the American
Diabetes Association of a fasting plasma glucose concentration between 5.6 mmol/L and 6.9 mmol/L and a 2-h
post-glucose load -7.8 mmol/L makes no difference to the interpretation of this case (12). About 3%–10% of
people per year with IFG develop diabetes (13). There are limited data on the preventability of progression of
IFG to diabetes by lifestyle measures. The cardiovascular risk profile of people with IFG should be checked
(blood pressure measurement, serum lipids etc.). IFG is also associated with the metabolic syndrome; impair-
ment of glucose metabolism is an optional criterion for the definition of the metabolic syndrome. Retesting may
be performed in 12 months’ time to assess change in glucose tolerance
2 Hypothyroidism whether overt or subclinical can have an adverse impact on the course of pregnancy or fetal
development and should be corrected before initiation of pregnancy (14). The Endocrine Society Clinical Practice
Guideline recommends adjustment of thyroxin (T4) therapy to attain a thyroid stimulating hormone (TSH)
-2.6 mU/L before conception based on the finding that babies born to women with overt or subclinical hypo-
thyroidism have an average intelligence quotient (IQ) score 7 points below the mean IQ score of babies born to
healthy women and women on T4 replacement (15). Fetal thyroid develops in the second trimester of pregnancy
followed by fetal thyroid hormone production in mid-gestation.
3 Use of age-specific PSA reference intervals appropriate for the assay used increases the sensitivity of the test in
younger men while maintaining 95% specificity. Those men found to have a prostate cancer with a PSA 2.6–4.0
mg/L have an 81% chance of their cancer being confined to the prostate gland (16). For a raised PSA that is
below 10 mg/L, free PSA (fPSA) may help in risk stratification. Likelihood of prostate cancer is high if fPSA -10%
and low if )25%. This patient should at least have a repeat PSA"fPSA in 1 month and ideally should be referred
to a urologist, especially if there is a strong family history. The urologist can repeat one or more tests and
recommend a transrectal ultrasound and biopsy of the prostate if necessary.
4 According to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative CKD classification
these eGFR results would place this patient in stage 3 CKD (17). While age-related reference intervals for serum
creatinine or eGFR are not recommended (17), eGFR does decline with age generally, although it is possible that
the decline is seen mainly in those with hypertension (18). Deciding if the decline is due to pathology or not is
not straightforward, and the results should be interpreted with caution. The Australian Creatinine Consensus
Working Party has concluded that ‘‘it was appropriate to advise medical practitioners that, in people aged
G70 years, eGFR values in the range 45–59 mL/min/1.73 m2, if stable over time and unaccompanied by other
evidence of kidney damage (e.g., proteinuria, hematuria etc.), may be interpreted as typical for this age group
and are unlikely to be associated with CKD complications (19).’’
5 The main therapeutic target for lipid lowering therapy in coronary heart disease (CHD) is LDL cholesterol. LDL-
lowering therapy reduces total mortality, coronary mortality, major coronary events, coronary artery procedures,
and stroke in persons with established CHD (20). The National Cholesterol Education Program Adult Treatment
Panel (NCEP ATP) III guidelines suggest an LDL cholesterol level of -2.6 mmol/L as optimal for secondary
prevention in established CHD and for persons with CHD risk equivalents (20). National guidelines may vary
e.g., the National Heart Foundation of Australia guidelines recommend an LDL cholesterol target -2.0 mmol/L
in therapy for secondary prevention (10).
IFG, impaired fasting glucose; PSA, prostate specific antigen; CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; LDL, low-density lipoprotein; T4, thyroxin.
snapshot of commenting ability among pathologists
and laboratory scientists in the region. The comments
of the participants were not individually assessed as
the main educational component was the general
feedback offered in the form of a commentary by the
Program Committee as well as a case discussion
(Table 9). Scoring the comments or some feedback to
individual participants on the appropriateness may be
done in the future (6, 8). The five reports circulated
reflected common and important problems encoun-
tered in clinical chemistry investigations with which
practising clinical chemists should be familiar. The
somewhat artificial environment of the study has to
be acknowledged, since in many real-life settings the
interpreter would have the opportunity to review the
entire medical record of the patient if necessary, and
may also be able to discuss issues of concern with
the ordering clinician. However, the quality of the
comments attached to the cases by participants in this
study was diverse; some responses received from the
participants reflected suboptimal or misleading inter-
pretation and advice which cannot be accounted for
by lack of information.
The effectiveness of a diagnostic clinical laboratory
depends on the selection of appropriate tests, accu-
rate and timely measurement and reporting of results
for the correct patients, and appropriate interpretation
of the results and action. The laboratory has a role in
each of these steps. It is an interesting paradox that
while major progress is being made in all aspects of
measurement in order to produce accurate and pre-
cise results, with ever shorter turn-around of results
due to improvements in information technology and
auto validation rules, and appropriate test selection
due in part to electronic order entry, the interpretation
of results has not seen similar improvements. Inter-
pretation has remained largely a manual activity
despite some attempts at the development of expert
systems (21). In any case, even the quality of the inter-
pretation offered by an expert system will be depend-
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ent on the knowledge and commenting skills of the
person building the knowledge base. Proficiency test-
ing of this activity has only recently been attempted
(22). Narrative interpretative comments are still a
voluntary and unregulated aspect of a laboratory
result. Lack of clinical information provided with test
requests and medico-legal implications of inappropri-
ate interpretative advice are some limiting factors. In
the future, interpretative commenting may become
part of a contractual requirement – as tests become
more complex, population-specific and qualitative in
their nature. Education in these activities is an impor-
tant part of training as well as continuing professional
development of laboratory personnel. The APFCB and
its members represent postgraduate specialist socie-
ties comprised of practising laboratory professionals,
and the individual participants in this program were
pathologists and mainly senior scientists. The com-
ments received in this program are reflective of lab-
oratory practice in the Asia-Pacific region.
The voluntary nature of the study might be expect-
ed to be biased toward laboratories that perform bet-
ter than average with their interpretive comments.
Therefore, the results of this program as well as other
published studies suggest that there is considerable
room for improvement in the quality of interpretative
comments offered by laboratory professionals (6).
Professional organizations have a role in the educa-
tion of laboratory personnel, both pathologists and
scientists, in interpretative commenting on laboratory
results. The performance of pathologists was not sig-
nificantly different to that of the scientists in terms of
the mean score obtained. This may be surprising, but
underscores the need for training pathologist in inter-
pretative commenting as part of their education.
Whilst the case studies point out some regional dif-
ferences in guidelines in interpretation, the discussion
shows that such a program can operate across
borders, especially as professionals should be aware
of any existing regional debates regarding inter-
pretation.
The educational value of programs such as this
would be enhanced by individualized feedback about
participants’ own comments. Scoring comments is an
obvious strategy, although it could be somewhat sub-
jective and may lack consistency. While giving a score
for comments may be helpful to enable participants
to assess their standard of commenting, individual
feedback on each aspect of a comment would be
more useful educationally. However, such individu-
alized feedback is very labor intensive. Another
approach used is the analysis of comments by clas-
sifying common key-phrases in the comments as
preferred, inappropriate, etc.; which may retain the
educational usefulness of the feedback to participants
and be applicable where there are large numbers
of participants (6). Further work is needed to explore
and develop appropriate and useful methods for
evaluation of comments and educational feedback
to laboratory professionals who participate in this
activity. Whatever the strategy employed, the results
of our study indicate that training and continuing pro-
fessional development in the area of interpretative
commenting is important and needed in the regions
studied.
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